Risk assessment of venous thromboembolism in hematological cancer patients: a review.

abstract：:Introduction: There is emerging evidence linking the commensal gut microbiota with the development of cardiovascular disease and arterial thrombosis. In immunothrombosis, the host clotting system protects against the dissemination of invading microbes, not considering the huge number of microbes that interact with hos...

journal_title：Expert review of hematology

authors： Formes H,Reinhardt C

更新日期：2019-07-01 00:00:00

abstract：INTRODUCTION:Purine analogs made dramatic improvements for patients with hairy cell leukemia (HCL), but patients often relapse, require multiple treatments, and may become refractory. Major developments in treatment of relapsed/refractory HCL occurred with discovery of disease biology. New agents increase the complexit...

journal_title：Expert review of hematology

authors： Chihara D,Kreitman RJ

更新日期：2020-10-01 00:00:00

abstract：:Ofatumumab is a humanized second-generation monoclonal antibody with the affinity to a transmembrane protein CD20. In in vitro studies, it exhibits higher efficacy towards chronic lymphocytic leukemia (CLL) cells compared to rituximab, and it can be explained by the fact that its epitope on the target CD20 protein is ...

journal_title：Expert review of hematology

authors： Grosicki S

更新日期：2015-06-01 00:00:00

abstract：:Key paper evaluation: Craddock C, et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2019; 37: 580-8. Allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only potentially cura...

journal_title：Expert review of hematology

authors： Bewersdorf JP,Stahl M,Zeidan AM

更新日期：2019-08-01 00:00:00

abstract：:Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in combination with chemotherapy. Over the last few years, several new mAbs have been developed and investigated in CLL. The most promising newe...

journal_title：Expert review of hematology

authors： Robak T

更新日期：2014-12-01 00:00:00

abstract：:Professor John Gribben is Chair of the International Workshop on non-Hodgkin Lymphoma and the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Bart's Cancer Institute, London, UK, a Cancer Research UK Centre of Excellence. His doctoral studies were performed at University College London...

journal_title：Expert review of hematology

authors： Gribben J

更新日期：2013-04-01 00:00:00

abstract：INTRODUCTION:Acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia that carries poor prognosis in adults especially in the setting of high risk cytogenetics and relapsed/refractory (R/R) disease. Advancements in immunotherapy have led to the development of several monoclonal antibodies (MoAbs) and chimer...

journal_title：Expert review of hematology

authors： Valecha GK,Ibrahim U,Ghanem S,Asti D,Atallah JP,Terjanian T

更新日期：2017-09-01 00:00:00

abstract：:Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count that has persisted for more than 12 months. Patients with severe, symptomatic disease may have significant morbidity and require treatment. Historically, the underlying cause of ITP was believed to be accelerated plat...

journal_title：Expert review of hematology

authors： Cheng G

更新日期：2011-06-01 00:00:00

abstract：:Introduction: The purpose of this article is to review which data about hemophilia are currently provided by the Cochrane database of systematic reviews (CDBSR). Methodological consideration: All statements about hemophilia in the Cochrane Collaboration are based on evidence generated in randomized controlled clinical...

journal_title：Expert review of hematology

authors： Rodriguez-Merchan EC

更新日期：2019-11-01 00:00:00

abstract：INTRODUCTION:Ferumoxytol is a superparamagnetic molecule originally developed as a contrast agent for magnetic resonance imaging. Elemental iron is contained within the carbohydrate core and is released slowly after infusion allowing a large dose of iron to be administered in a short period of time. Ferumoxytol, origin...

journal_title：Expert review of hematology

authors： Auerbach M,Chertow GM,Rosner M

更新日期：2018-10-01 00:00:00

abstract：INTRODUCTION:The discovery of the factor V Leiden (FVL) missense mutation (Arg506Gln) causing factor V resistance to the anticoagulant action of activated protein C was a landmark that allowed a better understanding of the basis of inherited thrombotic risk. FVL mutation is currently the most common known hereditary de...

journal_title：Expert review of hematology

authors： Campello E,Spiezia L,Simioni P

更新日期：2016-12-01 00:00:00

abstract：:Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a diffuse proliferation of medium-to-large B cells associated with...

journal_title：Expert review of hematology

authors： Martelli M,Di Rocco A,Russo E,Perrone S,Foà R

更新日期：2015-04-01 00:00:00

abstract：INTRODUCTION:While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians. Andexanet alfa is ...

journal_title：Expert review of hematology

authors： Cervi A,Crowther M

更新日期：2018-11-01 00:00:00

abstract：:Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type. Although the prognosis of chronic and smoldering-type ATL is relatively good,...

journal_title：Expert review of hematology

authors： Tanosaki R,Tobinai K

更新日期：2010-12-01 00:00:00

abstract：:Although guidelines exist to deal with some aspects of platelet transfusion practice, many important clinical issues have not been addressed in large randomized controlled trials (RCTs). Slichter et al. conducted a RCT of prophylactic platelet transfusions to determine the effects of the dose of platelets on clinical ...

journal_title：Expert review of hematology

authors： Cid J,Lozano M

更新日期：2010-08-01 00:00:00

abstract：:Hematopoietic stem cells can be mobilized out of the bone marrow into the blood for the reconstitution of hematopoiesis following high-dose therapy. Methods to improve mobilization efficiency and yields are rapidly emerging. Traditional methods include chemotherapy with or without myeloid growth factors. Plerixafor, a...

journal_title：Expert review of hematology

authors： Damon LE,Damon LE

更新日期：2009-12-01 00:00:00

abstract：:Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct...

journal_title：Expert review of hematology

authors： Figueiredo L,Cole PD,Drachtman RA

更新日期：2016-03-01 00:00:00

abstract：INTRODUCTION:Peripheral T cell lymphomas (PTCL) are a heterogenous group of lymphoproliferative disorders which are generally not curable with conventional chemotherapy and associated with inferior outcomes. Pralatrexate is a novel folate analog, the first FDA approved drug) for the treatment of relapsed/refractory (R/...

journal_title：Expert review of hematology

authors： Jennifer C Z,Sara Mohamed J,Salma A,Francine F

更新日期：2020-06-01 00:00:00

abstract：:Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for th...

journal_title：Expert review of hematology

authors： Fathi AT,Levis M

更新日期：2009-02-01 00:00:00

abstract：:Introduction: Severe sickle cell disease is associated with progressive end-organ damage and early mortality in adults. While allogeneic hematopoietic cell transplant from a matched related donor is curative, the vast majority of patients do not have a compatible sibling. Accordingly, platforms using haploidentical do...

journal_title：Expert review of hematology

authors： Patel DA,Akinsete AM,Connelly JA,Kassim AA

更新日期：2019-09-01 00:00:00

abstract：INTRODUCTION:Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more often requiring active surveillance rather than intervention. Despite the indolent nature of CLL/SLL, treatment is likely indicated in a patients' lifetime. Recent changes in the t...

journal_title：Expert review of hematology

authors： Tees MT,Flinn IW

更新日期：2017-02-01 00:00:00

abstract：INTRODUCTION:Treatment of elderly patients with acute leukemia is challenging. Older age is associated with increased risk of treatment-related toxicity. Currently, no consensus exists regarding optimal therapy in this patient population. Areas covered: The following review is a comprehensive summary of various therape...

journal_title：Expert review of hematology

authors： Thomas X

更新日期：2017-11-01 00:00:00

abstract：INTRODUCTION:Primary plasma cell leukemia (PPCL) is one of the most aggressive hematological malignancies. The prognosis of PPCL patients remains poor, although some improvements have been made in recent years. Areas covered: In this review recent clinical and biological advances in PPCL are reported. Some recommendati...

journal_title：Expert review of hematology

authors： Musto P,Statuto T,Valvano L,Grieco V,Nozza F,Vona G,Bochicchio GB,La Rocca F,D'Auria F

更新日期：2019-04-01 00:00:00

abstract：INTRODUCTION:Immune surveillance is the dynamic process whereby the immune system identifies and kills tumor cells based on their aberrant expression of stress-related surface molecules or presentation of tumor neoantigens. It plays a crucial role in controlling the initiation and progression of hematologic cancers suc...

journal_title：Expert review of hematology

authors： Nesic M,El-Galaly TC,Bøgsted M,Pedersen IS,Dybkær K

更新日期：2020-06-01 00:00:00

abstract：:Over two-thirds of newly diagnosed multiple myeloma are over 65 years. The treatment goals for the non-transplant-eligible patients should be to prolong survival by achieving the best response, while ensuring quality of life. New upfront treatment combinations based on first generation of novel proteasome inhibitors a...

journal_title：Expert review of hematology

authors： Mateos MV,Leleu X,Palumbo A,San Miguel JF

更新日期：2014-02-01 00:00:00

abstract：INTRODUCTION:First and second generation tyrosine kinase inhibitors, represent a new, fully biologic and targeted approach to chronic lymphocytic leukemia and allowed to obtain high responses and acceptable tolerability even in elderly and high risk patients. On the other hand, prolonged experience with these agents ha...

journal_title：Expert review of hematology

authors： Frustaci AM,Montillo M,Picardi P,Mazzucchelli M,Cairoli R,Tedeschi A

更新日期：2016-07-01 00:00:00

abstract：:Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, consumption thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, the specific von Willebrand factor (VWF)-cl...

journal_title：Expert review of hematology

authors： Joly BS,Coppo P,Veyradier A

更新日期：2019-06-01 00:00:00

abstract：:Hemopoietic stem-cell transplant patients may require intensive blood component support. Complications of transfusions include transmission of viral and bacterial infections, transfusion-associated graft-versus-host disease and transfusion-related acute lung injury. Alloimmunization to red cell antigens may cause diff...

journal_title：Expert review of hematology

authors： Radia R,Pamphilon D

更新日期：2011-04-01 00:00:00

abstract：:Adult immune thrombocytopenia was previously considered a benign disease affecting young people and with a low risk of severe bleeding. This view was challenged by studies published during the past decade, as the median age of adult immune thrombocytopenia patients has been found to be 55-60 years and the incidence in...

journal_title：Expert review of hematology

authors： Frederiksen H,Christiansen CF,Nørgaard M

更新日期：2012-04-01 00:00:00

abstract：BACKGROUND:Polycythemia occurs in 1 to 5% of neonates and is associated with complications, including an increased risk of thrombocytopenia. OBJECTIVE:To evaluate incidence, risk factors, management and outcome of thrombocytopenia in neonates with polycythemia. STUDY DESIGN:All neonates with polycythemia admitted to ...

journal_title：Expert review of hematology

authors： Vlug RD,Lopriore E,Janssen M,Middeldorp JM,Rath ME,Smits-Wintjens VE

更新日期：2015-02-01 00:00:00